Literature DB >> 17396289

Multiple myeloma therapies.

Matthew Strobeck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17396289     DOI： 10.1038/nrd2269

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma.

Authors:  Suyun Wang; Zhiyong Cheng; Xiaoyang Yang; Kai Deng; Yan Cao; Hao Chen; Ling Pan
Journal:  Int J Hematol       Date:  2010-06-26       Impact factor: 2.490

2.  A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.

Authors:  Ajita V Singh; Madhavi Bandi; Noopur Raje; Paul Richardson; Michael A Palladino; Dharminder Chauhan; Kenneth C Anderson
Journal:  Blood       Date:  2011-03-31       Impact factor: 22.113

Review 3.  Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.

Authors:  James J Driscoll; Jason Burris; Christina M Annunziata
Journal:  Am J Ther       Date:  2012-03       Impact factor: 2.688

4.  CYT997 causes apoptosis in human multiple myeloma.

Authors:  Katherine Monaghan; Tiffany Khong; Gregg Smith; Andrew Spencer
Journal:  Invest New Drugs       Date:  2009-11-12       Impact factor: 3.850

5.  Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

Authors:  Irma Airoldi; Claudia Cocco; Nicola Giuliani; Marina Ferrarini; Simona Colla; Emanuela Ognio; Giuseppe Taverniti; Emma Di Carlo; Giovanna Cutrona; Vittorio Perfetti; Vittorio Rizzoli; Domenico Ribatti; Vito Pistoia
Journal:  Blood       Date:  2008-05-12       Impact factor: 22.113

6.  Microvesicles secreted from human multiple myeloma cells promote angiogenesis.

Authors:  Yan Liu; Xiao-jian Zhu; Chen Zeng; Pin-hui Wu; Hong-xiang Wang; Zhi-chao Chen; Qiu-bai Li
Journal:  Acta Pharmacol Sin       Date:  2013-12-30       Impact factor: 6.150

7.  Marine compounds inhibit growth of multiple myeloma in vitro and in vivo.

Authors:  Normann Steiner; Domenico Ribatti; Wolfgang Willenbacher; Karin Jöhrer; Johann Kern; Christian Marinaccio; Miguel Aracil; Luis F García-Fernández; Guenther Gastl; Gerold Untergasser; Eberhard Gunsilius
Journal:  Oncotarget       Date:  2015-04-10

8.  BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Authors:  Mohamed-Amine Hamouda; Arnaud Jacquel; Guillaume Robert; Alexandre Puissant; Valentine Richez; Romeo Cassel; Nina Fenouille; Sandrine Roulland; Jerome Gilleron; Emmanuel Griessinger; Alix Dubois; Beatrice Bailly-Maitre; Diogo Goncalves; Aude Mallavialle; Pascal Colosetti; Sandrine Marchetti; Martine Amiot; Patricia Gomez-Bougie; Nathalie Rochet; Marcel Deckert; Herve Avet-Loiseau; Paul Hofman; Jean-Michel Karsenti; Pierre-Yves Jeandel; Claudine Blin-Wakkach; Bertrand Nadel; Thomas Cluzeau; Kenneth C Anderson; Jean-Gabriel Fuzibet; Patrick Auberger; Frederic Luciano
Journal:  J Exp Med       Date:  2016-07-25       Impact factor: 14.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.